Hill BT, Chen Y, Jagadeesh D, Dean R, et al. Lenalidomide, rituximab (R(2)), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leuk Lymphoma 2024 Mar 8:1-6. doi: 10.1080/10428194.2024.2325636.
PMID: 38456694